A diluent for preserving foot-and-mouth disease inactivated virus solution

By using a multi-component, precisely proportioned antigen diluent, the problem of poor virus stability in foot-and-mouth disease virus diluents has been solved, enabling long-term preservation of virus particles and stability of vaccine quality. This method is suitable for routine laboratories and large-scale vaccine production.

CN123107938APending Publication Date: 2026-11-17INNER MONGOLIA BIGVET BIOTECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611073392.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-07-20
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing foot-and-mouth disease virus diluents exhibit poor virus stability during storage, especially the 146S intact particles, which are easily damaged and cannot meet the requirements for long-term storage. This is mainly due to unreasonable diluent composition design and insufficient optimization of component ratios, resulting in insufficient buffering capacity and poor protective effect.

Method used

The antigen diluent uses a multi-component, precisely proportioned solution, including specific concentrations of pH buffers, protectants, and ion-regulating components, which work synergistically to improve the stability of virus preservation. The specific components are Tris base, KH2PO4, KOH, potassium chloride, glucose, glycine, arginine, glycerol, PEG6000, leucine inhibitor peptide, and PMSF, ensuring pH stability and protection of the virus particle surface.

Benefits of technology

After being stored at 2-8℃ for 12 months, the loss rate of intact 146S particles was only 4.1%, which is significantly lower than that of existing technologies, ensuring the immune activity and quality stability of the vaccine, and reducing production costs and operational complexity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

This invention relates to the field of antigen diluent technology, and more particularly to a diluent for preserving inactivated foot-and-mouth disease virus (FMDV) solution. The diluent for preserving inactivated FMDV solution comprises the following raw materials: pH buffer; potassium chloride: 0.16–0.2 mol / L; glucose: 0.015–0.02 mol / L; glycine: 0.07–0.1 mol / L; arginine: 0.035–0.05 mol / L; glycerol: 6–8 wt%; PEG6000: 1.5–2 wt%; leucine inhibitor peptide: 2–3 μg / mL; PMSF: 0.35–0.5 mmol / L; calcium chloride: 0.0007–0.001 mol / L; and a pH of 7.2–7.6. The diluent of this invention improves the preservation stability of FMDV and the stability of the vaccine preparation process, reduces the decrease in 146S content, and extends the preservation time, providing strong support for FMDV research, diagnosis, and vaccine production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of antigen diluent technology, and more particularly to a diluent for preserving foot-and-mouth disease inactivated virus solution. Background Technology

[0002] Foot-and-mouth disease (FMD) is caused by foot-and-mouth disease virus (FMDV). As an acute, febrile, and highly contagious disease, it primarily affects cloven-hoofed animals, causing large-scale reductions in livestock production. Therefore, maintaining the stability of inactivated virus solution is a core requirement in the research, diagnosis, and vaccine production of FMDV. Furthermore, the stability of intact 146S virus particles, as a key carrier of vaccine immunogenicity, directly determines the subsequent application value of the virus and the efficacy of the vaccine. Currently, commonly used foot-and-mouth disease virus (FMD) diluents include: 1) Ordinary physiological saline preservation: Purified FMD virus is mixed with physiological saline in a specific ratio for preservation. Physiological saline, mainly composed of sodium chloride, maintains a certain osmotic pressure. 2) Glycerol-buffered buffer preservation: Composed of a certain concentration of glycerol and a simple buffer solution. Glycerol provides some antifreeze and protection, while the buffer solution maintains a specific pH environment. Ordinary physiological saline lacks buffering capacity, and its pH value easily changes during preservation. Furthermore, it lacks components that protect the viral structure, resulting in poor viral stability, a rapid decrease in 146S concentration, and a short preservation time. While the glycerol-buffered buffer preservation method can extend the virus preservation time to some extent, it does not provide comprehensive protection for viral particles. With prolonged preservation, the viral titer still decreases significantly, and its protection of intact 146S particles is ineffective, failing to meet the requirements for long-term preservation.

[0003] The aforementioned methods generally face the problem of poor viral stability during preservation: as preservation time increases, viral titers decrease significantly, and viral structures are easily damaged, especially intact 146S particles. This not only seriously affects subsequent viral research and applications but also brings many inconveniences to vaccine production and other related work. In-depth research has revealed that the root causes of the problems with existing diluents lie in two core dimensions: the composition of the diluent and the proportions of its components, specifically as follows: From the perspective of diluent composition, existing solutions suffer from unreasonable component design and the absence or insufficiency of key functional components, failing to effectively support the long-term maintenance of viral structure and activity. On the one hand, some diluents lack sufficient buffering components or use only a single buffering component, resulting in insufficient buffering capacity. During storage, the pH value is prone to significant fluctuations, damaging the structural stability of viral particles. On the other hand, some diluents do not add suitable protective agents, or the type of protective agent is inappropriate, failing to form an effective protective film on the surface of viral particles. This makes it difficult to prevent the aggregation and rupture of viral particles, further exacerbating the loss of intact 146S particles. From the perspective of component ratio, even though some existing diluents use functional components such as phosphate-buffered saline (PBS) as a buffer system and sugars as a protective agent, there is a general problem of arbitrary component ratio design. The synergistic effect of each component ratio on viral stability has not been studied in depth, resulting in the inability of the components to form an effective synergistic effect, and they may even interfere with each other. The aforementioned issues arising from the "diluent composition" and "component ratios" collectively prevent existing diluents from meeting the requirements for long-term stable virus preservation. Therefore, developing an antigen diluent "based on precise synergistic proportions of multiple components, significantly improving 146S stability" is crucial. It requires addressing the shortcomings in component design, ensuring the completeness and compatibility of key functional components, and overcoming the limitation of "ignoring ratio optimization" in existing technologies. Achieving functional synergy through scientifically optimizing the component ratios is of paramount importance for resolving the pain points of existing technologies and improving the stability of foot-and-mouth disease virus diluents. Summary of the Invention

[0004] The purpose of this invention is to address the aforementioned shortcomings of the prior art by providing a diluent for preserving foot-and-mouth disease inactivated virus solution.

[0005] The purpose of this invention is to provide a diluent for preserving foot-and-mouth disease inactivated virus solution, the raw materials of which include: pH buffer; Potassium chloride: 0.16–0.2 mol / L; Glucose: 0.015–0.02 mol / L; Glycine: 0.07–0.1 mol / L; Arginine: 0.035–0.05 mol / L; Glycerin: 6-8 wt% PEG6000: 1.5–2 wt%; Leucinogenase peptide: 2-3 μg / mL; PMSF: 0.35–0.5 mmol / L; Calcium chloride: 0.0007~0.001mol / L; The pH of the diluent is 7.2-7.6.

[0006] Furthermore, pH buffers include Tris base, KH2PO4, and KOH.

[0007] Furthermore, Tris base: 0.16–0.2 mol / L; KH₂PO₄: 0.06–0.08 mol / L; KOH: 1 mol / L.

[0008] Furthermore, potassium chloride: 0.2 mol / L; calcium chloride: 0.001 mol / L.

[0009] Furthermore, the concentrations were: glucose: 0.02 mol / L; glycine: 0.1 mol / L; arginine: 0.05 mol / L.

[0010] Furthermore, glycerin: 8 wt%.

[0011] Furthermore, PEG6000: 2 wt%.

[0012] Furthermore, the leucinogenase peptide concentration was 3 μg / mL, and the PMSF concentration was 0.5 mmol / L.

[0013] This invention provides a diluent for preserving inactivated foot-and-mouth disease virus (FMDV) solution. By precisely designing the addition ratio of buffers, protectants, and ion-regulating components, the diluent achieves a synergistic effect of multiple components, improving the preservation stability of FMDV and the stability of the vaccine preparation process, reducing the decline in 146S content, and extending the preservation time, thus providing strong support for FMDV research, diagnosis, and vaccine production.

[0014] The specific beneficial effects are as follows: (1) It can maintain the structural integrity of the core antigen (146S) of foot-and-mouth disease virus for a long time: After being stored at 2-8℃ for 12 months, the loss rate of 146S in the vaccine prepared with this diluent is only 4.1%, which is far lower than the loss level of existing technologies, and can effectively ensure the immune activity and quality stability of the vaccine.

[0015] (2) The buffer components are matched in a specific ratio, which greatly improves the buffering capacity compared with the conventional ratio and avoids the damage of pH imbalance to the 146S structure; the synergistic system formed by the ionic components solves the problem of charge imbalance and aggregation of virus particles caused by a single ion type; the combination of multiple protective agents in a precise ratio enhances the density of the protective film on the surface of the virus and avoids the risk of the protective film falling off during the vaccine emulsification process.

[0016] (3) All components used in the formula are commercially available analytical grade reagents and do not require special preparation processes. The preparation process can be completed in a conventional laboratory or production workshop, which not only meets the standardized requirements of large-scale vaccine production, but also effectively reduces the production costs and operational complexity of enterprises. Detailed Implementation

[0017] The following are specific embodiments of the present invention, which further describe the technical solution of the present invention, but the present invention is not limited to these embodiments.

[0018] Definitions of abbreviations and key terms 1. Foot-and-mouth disease virus (FMDV): This is a pathogen that causes foot-and-mouth disease (FMD) and belongs to the genus FMDV in the family Picornaviridae. It is a highly contagious virus that mainly infects cloven-hoofed animals (such as cattle, sheep, pigs, and deer), posing a significant threat to livestock farming.

[0019] 2.146S: The complete viral particle of foot-and-mouth disease virus, which is immunogenic and is the core functional component for inducing an immune response in animals through vaccines. Its content and stability directly determine the efficacy of the vaccine.

[0020] 3. Antigen diluent: A buffer protection system specifically designed for diluting foot-and-mouth disease inactivated virus solution, used to maintain the stability of virus particle structure, protect 146S integrity, and extend the virus storage period.

[0021] 4. PEG6000: Polyethylene glycol 6000, used as a stabilizer and anti-aggregation agent.

[0022] 5. PMSF: Benzyl sulfonyl fluoride, a serine protease inhibitor.

[0023] 6. Leucinase peptide: a serine / cysteine ​​protease inhibitor.

[0024] This invention provides a method for effectively protecting the stability of foot-and-mouth disease virus particles. The core of this method is to dilute the inactivated foot-and-mouth disease virus solution with a multi-component, precisely proportioned, synergistic antigen diluent, reducing losses during vaccine preparation. The specific steps and key proportions are designed as follows: Physicochemical properties of vaccines prepared with different antigen diluents Vaccines were prepared using seven different types of antigen diluents (PBS 1, PBS 2, PBS 3, PBS 4, PBS 5, PBS 6, and PBS 7) (the components are shown in Table 1), and the physicochemical properties of the vaccines were tested.

[0025] (1) Preparation of aqueous phase of vaccine: Based on the target 146S content and the original 146S concentration of the inactivated virus solution, the amount of antigen diluent to be added is accurately calculated, and the inactivated virus solution and antigen diluent are mixed in proportion to prepare the aqueous phase.

[0026] (2) Vaccine emulsification and preservation: The prepared aqueous phase and biphasic adjuvant were mixed at a mass ratio of 1:1 and emulsified continuously at a stirring speed of 480 rpm for 15 min to form a homogeneous water-in-oil-in-water vaccine. After emulsification, the vaccine was placed in an environment of 2-8℃ and stored for 12 h. The physicochemical indicators of the vaccine after 12 h of storage were tested, including 146S content and physical properties. (3) Repetition and Elimination Criteria: To ensure the reliability and repeatability of the results, different batches of inactivated virus solution were selected and two parallel tests were conducted according to the same procedure (a total of three tests). If the physicochemical indicators (146S content, total protein content, physical properties) of a certain antigen diluent test group do not meet the vaccine quality standards in all three tests, the diluent will be directly eliminated.

[0027] (4) Conclusion: The physicochemical indicators of the 7 groups of antigen dilution vaccines were all qualified.

[0028] Storage stability of vaccines prepared with different antigen diluents The prepared vaccines underwent 12 months of long-term stability monitoring, with monthly testing of 146S content to quantify the protective effect of the antigen diluent. The "12-month average 146S loss rate" was used as the core indicator, and the vaccines were ranked from lowest to highest loss rate, with the lowest loss rate being the optimal solution. Detailed test results are shown in Table 2-5 (12-month summary and loss rate).

[0029] Table 1. Components of 7 different types of antigen diluents

[0030]

[0031]

[0032]

[0033]

[0034] Based on 12-month stability monitoring data of vaccines formulated with seven different antigen diluents, the average 146S loss rate over 12 months was used as the core evaluation indicator. A comprehensive analysis was conducted, combining this with trends in protein content changes: Diluents #1, #2, #3, and #4 had identical formulations, differing only in synergistic ratios, resulting in significant differences in antigen degradation rates. Diluents #5, #6, and #7 exhibited differences in composition, leading to large variations in degradation rates. The overall results indicate that PBS antigen diluent #3, through complementary components and precise synergistic ratios, effectively delays vaccine antigen degradation and is the optimal formulation.

[0035] Among all experimental groups, the vaccine prepared with PBS antigen diluent #3 showed the best antigen stability and protection. After being stored at 2-8°C for 12 months, the 146S loss rate was only 4.1%, which was significantly lower than the 146S loss level of the other 6 diluents.

[0036] Composition and precise ratio of antigen diluent The antigen diluent of this invention is composed of a buffer component, a protective agent component, an ion regulating component, and an auxiliary component. The specific formulation and synergistic effects are shown in Table 6.

[0037] Table 6

[0038] This invention achieves core technological innovation to address the preservation requirements of foot-and-mouth disease virus. Through targeted experimental screening, it obtains a precise and optimized ratio of each component. The core technological advantages are as follows: (1) Construct a Tris base + potassium dihydrogen phosphate + KOH exclusive buffer pair with the above concentration range, which is precisely adapted to the core pH stable range of foot-and-mouth disease virus 7.2-7.6, and achieves precise targeting of buffering capacity; (2) Design a potassium chloride + calcium chloride + arginine synergistic ion system within the above concentration range, precisely control the ionic strength and osmotic pressure of the solution, stabilize the surface charge of virus particles, and avoid problems such as virus aggregation and structural rupture from the root cause; (3) The combination of glucose + glycine + arginine + glycerol + PEG6000 + leucine inhibitory peptide + PMSF in the above concentration range greatly improves the stability protection efficiency against foot-and-mouth disease virus, which is significantly better than the conventional preservation solution system.

[0039] This invention uses a three-dimensional synergistic system of "buffer-ion-protection" to form a diluent for preserving foot-and-mouth disease inactivated virus solution. This allows the foot-and-mouth disease virus antigen to be emulsified into a vaccine and stored at 2-8℃ for 12 months, with the 146S content decreasing by no more than 6.5%.

[0040] For any points not covered above, existing technologies shall apply.

[0041] Although specific embodiments of the present invention have been described in detail by way of examples, those skilled in the art should understand that the above examples are for illustrative purposes only and are not intended to limit the scope of the invention. Those skilled in the art can make various modifications or additions to the described specific embodiments or use similar methods to replace them, without departing from the direction of the invention or exceeding the scope defined by the appended claims. Those skilled in the art should understand that any modifications, equivalent substitutions, improvements, etc., made to the above embodiments based on the technical essence of the present invention should be included within the protection scope of the present invention.

Claims

1. A diluent for preserving foot-and-mouth disease inactivated virus solution, characterized in that, Raw materials include: pH buffer; Potassium chloride: 0.16–0.2 mol / L; Glucose: 0.015–0.02 mol / L; Glycine: 0.07–0.1 mol / L; Arginine: 0.035–0.05 mol / L; Glycerin: 6-8 wt% PEG6000: 1.5–2 wt%; Leucinogenase peptide: 2-3 μg / mL; PMSF: 0.35–0.5 mmol / L; Calcium chloride: 0.0007~0.001mol / L; The pH of the diluent is 7.2-7.

6.

2. The diluent for preserving foot-and-mouth disease inactivated virus solution as described in claim 1, characterized in that, pH buffers include Tris base, KH2PO4, and KOH.

3. The diluent for preserving foot-and-mouth disease inactivated virus solution as described in claim 1, characterized in that, Tris base: 0.16–0.2 mol / L; KH₂PO₄: 0.06–0.08 mol / L; KOH: 1 mol / L.

4. The diluent for preserving foot-and-mouth disease inactivated virus solution as described in claim 3, characterized in that, Potassium chloride: 0.2 mol / L; Calcium chloride: 0.001 mol / L.

5. The diluent for preserving foot-and-mouth disease inactivated virus solution as described in claim 4, characterized in that, Glucose: 0.02 mol / L; Glycine: 0.1 mol / L; Arginine: 0.05 mol / L.

6. A diluent for preserving foot-and-mouth disease inactivated virus solution as described in claim 3 or 4, characterized in that, Glycerin: 8 wt%.

7. The diluent for preserving foot-and-mouth disease inactivated virus solution as described in claim 6, characterized in that, PEG6000: 2 wt%.

8. The diluent for preserving foot-and-mouth disease inactivated virus solution as described in claim 7, characterized in that, Leucinogen: 3 μg / mL; PMSF: 0.5 mmol / L.